156 related articles for article (PubMed ID: 38777866)
1. A novel subtype based on driver methylation-transcription in lung adenocarcinoma.
Wang X; Xu Z; Zhao S; Song J; Yu Y; Yang H; Hou Y
J Cancer Res Clin Oncol; 2024 May; 150(5):269. PubMed ID: 38777866
[TBL] [Abstract][Full Text] [Related]
2. Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma.
Huang Z; Li B; Guo Y; Wu L; Kou F; Yang L
Front Immunol; 2021; 12():723172. PubMed ID: 34539658
[TBL] [Abstract][Full Text] [Related]
3. Molecular subtypes of lung adenocarcinoma present distinct immune tumor microenvironments.
Fukuda H; Arai K; Mizuno H; Nishito Y; Motoi N; Arai Y; Hiraoka N; Shibata T; Sonobe Y; Kayukawa Y; Hashimoto E; Takahashi M; Fujii E; Maruyama T; Kuwabara K; Nishizawa T; Mizoguchi Y; Yoshida Y; Watanabe SI; Yamashita M; Kitano S; Sakamoto H; Nagata Y; Mitsumori R; Ozaki K; Niida S; Kanai Y; Hirayama A; Soga T; Tsukada K; Yabuki N; Shimada M; Kitazawa T; Natori O; Sawada N; Kato A; Yoshida T; Yasuda K; Ochiai A; Tsunoda H; Aoki K
Cancer Sci; 2024 Jun; 115(6):1763-1777. PubMed ID: 38527308
[TBL] [Abstract][Full Text] [Related]
4. Multi-omics analysis of genomics, epigenomics and transcriptomics for molecular subtypes and core genes for lung adenocarcinoma.
Zhao Y; Gao Y; Xu X; Zhou J; Wang H
BMC Cancer; 2021 Mar; 21(1):257. PubMed ID: 33750346
[TBL] [Abstract][Full Text] [Related]
5. Identification of Prognostic DNA Methylation Signatures in Lung Adenocarcinoma.
Wang P; Xu G; Gao E; Xu Y; Liang L; Jiang G; Duan L
Oxid Med Cell Longev; 2022; 2022():8802303. PubMed ID: 35814273
[TBL] [Abstract][Full Text] [Related]
6. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
[TBL] [Abstract][Full Text] [Related]
7. A prognosis-related molecular subtype for early-stage non-small lung cell carcinoma by multi-omics integration analysis.
Yang K; Wu Y
BMC Cancer; 2021 Feb; 21(1):128. PubMed ID: 33549049
[TBL] [Abstract][Full Text] [Related]
8. Construction of RNA Methylation Modification-immune-related lncRNA Molecular Subtypes and Prognostic Scoring System in Lung Adenocarcinoma.
Wang J; Shu J
Curr Med Chem; 2024; 31(12):1539-1560. PubMed ID: 37680151
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive molecular analyses of cuproptosis-related genes with regard to prognosis, immune landscape, and response to immune checkpoint blockers in lung adenocarcinoma.
Li R; Tong R; Zhang JL; Zhang Z; Deng M; Hou G
J Cancer Res Clin Oncol; 2024 May; 150(5):246. PubMed ID: 38722401
[TBL] [Abstract][Full Text] [Related]
10. Molecular subtypes based on ferroptosis-related genes and tumor microenvironment infiltration characterization in lung adenocarcinoma.
Zhang W; Yao S; Huang H; Zhou H; Zhou H; Wei Q; Bian T; Sun H; Li X; Zhang J; Liu Y
Oncoimmunology; 2021; 10(1):1959977. PubMed ID: 34527427
[TBL] [Abstract][Full Text] [Related]
11. DNA methylation-based lung adenocarcinoma subtypes can predict prognosis, recurrence, and immunotherapeutic implications.
Xu F; He L; Zhan X; Chen J; Xu H; Huang X; Li Y; Zheng X; Lin L; Chen Y
Aging (Albany NY); 2020 Nov; 12(24):25275-25293. PubMed ID: 33234739
[TBL] [Abstract][Full Text] [Related]
12. Multi-omics analysis of m
Wu X; Bai Z
Sci Rep; 2021 Oct; 11(1):20921. PubMed ID: 34686691
[TBL] [Abstract][Full Text] [Related]
13. Development and Validation of a DNA Methylation-related Classifier of Circulating Tumour Cells to Predict Prognosis and to provide a therapeutic strategy in Lung Adenocarcinoma.
Gu X; Huang X; Zhang X; Wang C
Int J Biol Sci; 2022; 18(13):4984-5000. PubMed ID: 35982906
[No Abstract] [Full Text] [Related]
14. The EMT-Related Genes GALNT3 and OAS1 are Associated with Immune Cell Infiltration and Poor Prognosis in Lung Adenocarcinoma.
Luo D; Fang M; Shao L; Wang J; Liang Y; Chen M; Gui X; Yan J; Wang W; Yu L; Fan X; Wu Q
Front Biosci (Landmark Ed); 2023 Oct; 28(10):271. PubMed ID: 37919050
[TBL] [Abstract][Full Text] [Related]
15. Identification and validation of tumor environment phenotypes in lung adenocarcinoma by integrative genome-scale analysis.
Bi G; Chen Z; Yang X; Liang J; Hu Z; Bian Y; Sui Q; Li R; Zhan C; Fan H
Cancer Immunol Immunother; 2020 Jul; 69(7):1293-1305. PubMed ID: 32189030
[TBL] [Abstract][Full Text] [Related]
16. KRT8 and KRT19, associated with EMT, are hypomethylated and overexpressed in lung adenocarcinoma and link to unfavorable prognosis.
Wang W; He J; Lu H; Kong Q; Lin S
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32519739
[TBL] [Abstract][Full Text] [Related]
17. Mining the Prognostic Role of DNA Methylation Heterogeneity in Lung Adenocarcinoma.
Liao H; Luo X; Huang Y; Yang X; Zheng Y; Qin X; Tan J; Shen P; Tian R; Cai W; Shi X; Deng X
Dis Markers; 2022; 2022():9389372. PubMed ID: 35677637
[TBL] [Abstract][Full Text] [Related]
18. SPOCK1, as a potential prognostic and therapeutic biomarker for lung adenocarcinoma, is associated with epithelial-mesenchymal transition and immune evasion.
Liu Y; Han T; Wu J; Zhou J; Guo J; Miao R; Xu Z; Xing Y; Bai Y; Hu D
J Transl Med; 2023 Dec; 21(1):909. PubMed ID: 38087364
[TBL] [Abstract][Full Text] [Related]
19. Construction and Validation of a Tumor Microenvironment-Based Scoring System to Evaluate Prognosis and Response to Immune Checkpoint Inhibitor Therapy in Lung Adenocarcinoma Patients.
Huang P; Xu L; Jin M; Li L; Ke Y; Zhang M; Zhang K; Lu K; Huang G
Genes (Basel); 2022 May; 13(6):. PubMed ID: 35741714
[TBL] [Abstract][Full Text] [Related]
20. Cystatin SN promotes epithelial-mesenchymal transition and serves as a prognostic biomarker in lung adenocarcinoma.
Yang J; Luo G; Li C; Zhao Z; Ju S; Li Q; Chen Z; Ding C; Tong X; Zhao J
BMC Cancer; 2022 May; 22(1):589. PubMed ID: 35637432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]